




























## **6. BIBLIOGRAFIA**

-  Akhondzadeh S., Kamalipour A., Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions (2000) 25,131-137
-  Casella C., Taglietti V. Fisiologia II (*la Goliardica Pavese s.r.l Pavia*) 1998
-  Cassano G.P., Tundo A. Manuale di Psichiatria UTET, Torino, 2000
-  Chen J.F., Huang Z., MA J. et al.: A<sub>2A</sub> adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. *J. Neurosci.* (1999)19:9192-9200
-  Corsi C., Melani A., Bianchi L., Pepeu G., Pedata F., Striatal A<sub>2A</sub> adenosine receptor differentially regulate spontaneous and K<sup>+</sup> - evoked glutamate release in vivo in young and aged rats. *Neuroreport* (1999); 10: 687-91.
-  Deckert J., Riederer P.; Up-regulation of striatal adenosine A<sub>2A</sub> receptors in schizophrenia *Neuroreport*. 2003 Mar 3; 14 (3):313-6
-  Dixon A.K., Gubitza A.K., Sirinathsinghji D.J.S., Richardson P.J. and Freeman T.C. (1996) Tissue distribution of adenosine receptor mRNAs in the rat. *Br J Pharmacol* 118: 1461-1468xx
-  Ferrè S., Fredholm B.B., Morelli M., Popoli P. and Fuxe K. (1997) Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. *Trends Neurosci* 20: 482-487
-  Fredholm B.B., Burnstock G., Harden K.T. and Spedding M. (1996) Receptor nomenclature. *Drug Dev Res.* 39: 461-466

-  Gao Y. and J.W. Philips , CGS15943, an adenosine A<sub>2</sub> receptor antagonist, reduces cerebral ischaemic injury in the Mongolian gerbil. *Life Sci.* 55(1994), pp.PL61-PL65.
-  Hillion J., Fuxe K.; Coaggregation, cointernalization, and codesensitization of adenosine A<sub>2A</sub> receptor and dopamine D<sub>2</sub> receptors. *J Biol Chem* .2002 May 17; 277(20)
-  Jones H.E., Griffiths R.R.; Oral caffeine maintenance potentiales the reinforcing and simulant subjective effects of intravenous nicotine in cigarette smokers. *Psichopharm* 2003 Jan; 165(3): 280-90
-  Jones P.A., R.A. Smith and T.W. Stone, Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A<sub>2A</sub> receptor agonists and antagonist. *Neuroscience* 85 (1998), pp. 229-237
-  Kamiya T., H. Nakata H.; Oligomerization of adenosine A<sub>2A</sub> e dopamine D<sub>2</sub> receptors in living cells Biochemical and biophysical communications 306 (2003) 544-549
-  Kapur S., Seeman P. Does fast Dissociation from the dopamine D<sub>2</sub> receptor Explain the action of Atypical Antipsychotics? A new Hipotesis. *Am j Psychiatry* 2001; 158:360369.
-  Kim J., Wess J., van-Rhee AM, Schoneberg T. and Jacobson K.A. (1995) Site-directed mutagenesis identifies residues involved in ligand recognition in the human A<sub>2A</sub> adenosine receptor. *J Biol Chem*
-  Nolte D., Lorenzen A., Lehr H.A., Zimmer F.J., Klotz K., Messner K., (1992) Naunyn Schm. Arch. Pharmac., 364,234-237.
-  Ongini E. and Fredholm B.B (1996) Pharmacology of adenosine A<sub>2A</sub> receptors. *Trends Pharmacol Sci* 17: 364-372

-  Palmer T.M. and Stiles G.L (1997) Identification of an A<sub>2A</sub> adenosine receptor domain specifically responsible for mediating short-term desensitization. *Biochemistry* 36:832-838
-  Parson Bruce et al Neuroleptics up-regulate Adenosine A<sub>2A</sub> receptors in rat striatum: Implication for the mechanism and the treatment of tardive Diskinesia *Journal of Neurochemistry* 1995
-  Popoli B., Betto P., Reggio R., Ricciarello G., Adenosine A<sub>2A</sub> receptor stimulation enhances striatal extracellular glutamate levels in rats. *Eur.J. Pharmacol.*(1995); 287: 215-7.
-  Ralevich V., Burnstock G.: receptors for purine and pyrimidines. *Pharm. Rev.*(1998)50: 413-492.
-  Rego A.C., Agostinho P., Melo J., Cunha R.A., Oliveira C.R., (2000), *Exp. Eye Res.* 70, 577-587.
-  Stehle J.H., Rikees S.A., Lee J.J., Weaver D.R., Deeds J.D., Reppert S.M., (1992). Molecular cloning and expression of the cDNA for novel A<sub>2</sub> – adenosine receptor subtype, *Mol. Endocrin.*, 6, 384-393.
-  Strange Philip G. Antipsychotic Drugs : Importance of dopamine receptors for Mechanism of Therapeutic Actions ald Side effects. *Pharmacological reviews* 53: 119-133, 2001.
-  Tricavelli M.L., Costa B., Tuscano D., Lucacchini A. Martini C., (2002). Up-regulation of A<sub>2A</sub> adenosine receptors by proinflammatoriy citikines in rat PC12 cells, *Biochemical Pharmacology*, 7377, 1-7.
-  Von Lubitz, R.C.S. Lin and K.A. Jacobson, Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A<sub>2A</sub> receptor agonist and antagonist. *Eur.J. Pharmacol.* 287 (1995), pp. 295-302.